Results 51 to 60 of about 15,808 (143)

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

open access: yesTransplant Infectious Disease, Volume 28, Issue 5, September/October 2026.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti   +6 more
wiley   +1 more source

Determination of Total and Free Ceftolozane and Tazobactam in Human Plasma and Interstitial Fluid by HPLC-UV

open access: yes, 2018
Ceftolozane/tazobactam is a new cephalosporin/beta-lactamase inhibitor combination. An HPLC-UV method is described for the determination of total and free ceftolozane and tazobactam in human plasma and in microdialysate of subcutaneous tissue ...
Kees, Frieder   +15 more
core   +1 more source

Global Distribution and Comparative Resistance Profiles of Escherichia coli Isolated From Bovine Meat and Meat Products: Evidence From Network Meta‐Analysis

open access: yesFood Science &Nutrition, Volume 14, Issue 7, July 2026.
Schematic overview of the study and its principal findings. E. coli isolated from bovine meat and meat products was evaluated for antimicrobial resistance using Bayesian network meta‐analysis. The graphical abstract highlights the antimicrobial resistance ranking based on SUCRA, showing high resistance to penicillin, doxycycline, amoxicillin ...
Yaser Khorram Del   +5 more
wiley   +1 more source

Ceftolozane-Tazobactam: A New-Generation Cephalosporin

open access: yes, 2015
Purpose. The chemistry, pharmacokinetic and pharmacodynamic properties, efficacy, and safety of the recently introduced combination antimicrobial agent ceftolozane-tazobactam are reviewed. Summary. Ceftolozane-tazobactam (Zerbaxa, Cubist Pharmaceuticals)
Lewis, Paul   +4 more
core   +1 more source

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination [PDF]

open access: yes, 2013
The management of infections caused by multidrug-resistant Gram-negative bacteria, particularly Pseudomonas aeruginosa, continues to be a significant challenge to clinicians.
Hsu, Donald I   +2 more
core   +1 more source

Ceftolozane-tazobactam in combination with fosfomycin for treatment of MDR/XDR P. aeruginosa infective endocarditis

open access: yesClinical Infection in Practice, 2019
Background: Infective endocarditis (IE) due to multi-drug (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa is rare. MDR P. aeruginosa infections are increasingly reported worldwide, and the choice of effective antimicrobials is limited ...
A. Prescott   +8 more
doaj   +1 more source

Guidelines for Essential Trauma Care: Second Edition (2026)

open access: yesWorld Journal of Surgery, Volume 50, Issue 6, Page 1409-1450, June 2026.
Injury is a major cause of death and disability globally, with the highest burden in low‐ and middle‐income countries (LMICs). Strengthening the organization and planning for trauma care (care of the injured) can improve care and lower mortality. In 2004, the International Association for Trauma Surgery and Intensive Care (IATSIC) and the World Health ...
Charles Mock   +41 more
wiley   +1 more source

Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015

open access: yes, 2017
The activity of ceftolozane-tazobactam was compared to the activities of 7 antimicrobials against 3,851 Pseudomonas aeruginosa isolates collected from 32 U.S.
Mariana Castanheira   +3 more
core   +1 more source

Zwitterionic Penicillin‐Derived Sulfone Inhibitor for Combating β‐Lactamase‐Mediated Antibiotic Resistance

open access: yesChemMedChem, Volume 21, Issue 9, 14 May 2026.
Combining enhanced permeability strategies with (2‐pyridyl)methylene substitution in the sulbactam scaffold led to a novel β‐lactamase inhibitor to combat β‐lactamase‐mediated resistance to β‐lactam antibiotics. The studies presented highlight the potential of compound 3 as a next‐generation β‐lactamase inhibitor for combating infections caused by ...
Diana Rodríguez   +4 more
wiley   +1 more source

Italian nationwide survey on pseudomonas aeruginosa from invasive infections: Activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers [PDF]

open access: yes, 2018
Objectives: Pseudomonas aeruginosa is a major cause of severe healthcare-associated infections and often shows MDR phenotypes. Ceftolozane/tazobactam is a new cephalosporin/b-lactamase inhibitor combination with potent activity against P.
Dusi P. A.   +29 more
core   +3 more sources

Home - About - Disclaimer - Privacy